Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

244
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
244
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab.

The Lancet regional health. Europe·2026
Same author

Paediatric medicines development for Duchenne muscular dystrophy: An EU regulatory perspective.

Journal of neuromuscular diseases·2025
Same author

Applying the EU Regulatory Framework to Determine the Benefit-Risk Profile of Psychedelics.

ACS pharmacology & translational science·2025
Same author

Knowledge gaps in psychedelic medicalisation: Clinical studies and regulatory aspects.

Neuroscience applied·2025
Same author

Comorbidities Are Associated With Unfavorable Outcome in Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Exploratory Study From the CROCTINO Cohort.

European journal of neurology·2025
Same author

The Tailored Biosimilar Approach: Expectations and Requirements.

Drugs·2025

Related Experiment Video

Updated: Jun 20, 2025

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

60.2K

Tofersen for SOD-1-associated amyotrophic lateral sclerosis

Marion Haberkamp1, Georgios Aislaitner2, Elena H Martínez-Lapiscina3

  • 1Unit Neurology, Psychiatry, Ophthalmology, Federal Institute for Drugs and Medical Devices, Bonn, Germany; Central Nervous System Working Party, European Medicines Agency, Amsterdam, Netherlands.

The Lancet. Neurology
|July 19, 2024
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells
11:12

Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells

Published on: October 4, 2017

7.2K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.6K

Related Experiment Videos

Last Updated: Jun 20, 2025

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

60.2K
Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells
11:12

Assay Development for High Content Quantification of Sod1 Mutant Protein Aggregate Formation in Living Cells

Published on: October 4, 2017

7.2K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.6K